Health Trials

Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

ConditionsChidamideR-CHOP ChemotherapyDLBCL - Diffuse Large B Cell LymphomaDouble-expressor Lymphoma (DEL)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital with Nanjing Medical University

About this trial

Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes

Eligibility criteria

Qualifiers

≥18 years of age;

Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;

Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;

Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;

Disqualifiers

Patients who meet any of the following criteria will be excluded from the study：

Currently enrolled in another clinical trial；

Received prior lymphoma treatment with alternative regimens before enrollment;

Presence of concurrent malignant tumors;

Trial design

Treatments tested in this trial

  • Chidamide plus R-CHOP

Treatment groups

148 Participants
are divided into 1 treatment group

Sponsors and collaborators

The First Affiliated Hospital with Nanjing Medical University

Lead sponsor

Source ClinicalTrials.gov